Leerink analyst Daina Graybosch downgraded iTeos Therapeutics (ITOS) to Market Perform from Outperform with a $9 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth
- iTeos Therapeutics downgraded to Neutral at JPMorgan after TIGIT program ended
- iTeos Therapeutics downgraded to Neutral from Overweight at JPMorgan
- iTeos Therapeutics Ends Collaboration with GSK
- GSK, iTeos ending development program for belrestotug